Schonfeld Strategic Advisors 13F: New $12M Stake in Alcon (ALC)

Schonfeld Strategic Advisors Initiates New Position in Alcon Inc.

Schonfeld Strategic Advisors added a fresh holding to its portfolio, purchasing 177,199 shares of eye care company Alcon Inc. (NYSE: ALC). The new investment appears in the fund's recent Form 13F filing with the Securities and Exchange Commission, which outlines portfolio holdings. Based on the cost basis provided in the filing, the total value of the newly established stake sits at approximately $11.89 million.

Inside Schonfeld's Recent Portfolio Moves

The acquisition marks a fresh bet on Alcon Inc. by the quantitative multi-strategy hedge fund. Because this transaction represents a brand-new stake, the fund held zero shares prior to the purchase. Institutional filings like this one reflect holdings as of a specific date and may not represent the fund's current position today.

Alcon Stock Performance and Valuation Context

Alcon shares trade on the New York Stock Exchange under the ticker ALC. The company operates within the healthcare sector, focusing on medical instruments and supplies. The stock changes hands against a 52-week trading range that spans from a low of $61.84 up to a high of $87.64.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on Alcon Inc., adjusting their targets through the late summer and fall of 2026. On August 11, 2026, Needham maintained its buy rating and set a $98.00 price target. The following day, JP Morgan maintained a neutral rating with a target of $78.40, while Mizuho kept an outperform rating alongside an $85.00 target. Later that month, Jefferies maintained a buy rating on September 22, 2026, with an adjusted target of $85.00. Moving into October, Needham reiterated its buy rating at $98.00 on September 15, 2026, while Barclays initiated coverage with an equal-weight rating and a $70.00 target on October 7, 2026. Shortly after, BTIG maintained its buy rating on October 12, 2026, adjusting its price target to $74.00.

What Alcon Inc. Does

Alcon Inc. researches, develops, manufactures, and distributes a wide array of eye care products across the globe. Headquartered in Geneva, Switzerland, the company serves patients and medical professionals through two main operating segments: Surgical and Vision Care. Its product catalog features equipment and consumables for cataract and refractive procedures, alongside daily disposable contact lenses and various ocular health solutions.

Looking Ahead After the Filing

Investors tracking Schonfeld's portfolio activity and Alcon's market trajectory will watch for subsequent regulatory filings to see if the fund adjusts its exposure. Form 13F filings provide a backward-looking glimpse into institutional strategies, and market participants often cross-reference these disclosures with upcoming corporate milestones and broader sector trends.